Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001209191-21-070768)

Filing Details

Accession Number:: 0001209191-21-070768
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-12-21 16:08:47
Reporting Period:: 2021-12-20

Accepted Time:: 2021-12-21 16:08:47
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434316	Fate Therapeutics Inc	FATE	Biological Products, (No Disgnostic Substances) (2836)	651311552

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1821530	Iii J Edward Dulac	C/O Fate Therapeutics, Inc. 12278 Scripps Summit Drive San Diego CA 92131	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2021-12-20	14,437	$35.52	126,381	No	4	M	Direct
Common Stock	Disposition	2021-12-20	15,977	$60.00	110,404	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Disposition	2021-12-20	14,437	$0.00	14,437	$35.52

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
128,238		2030-08-17	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 28, 2021.
The option shall vest as to 25% of the underlying shares on August 17, 2021 and thereafter on a monthly basis for 36 additional months, subject to the Reporting Person's continuous service to the Issuer as of each such vesting date.